ApothéCure - Creative Custom Compounds
Contact the Pharmacy by Phone or by Email
DFW Local: _ 972-960-6601 _ pharmacistapothecure.com
United States: _ 800-969-6601 _ pharmacistapothecure.com
Canada: _ 800-203-2158 _ intapothecure.com
Worldwide: _ 001-972-960-6601 _ intapothecure.com
 
 
 
 
 

ApothéCure - Custom Compounds

Neurological Therapies

Neural Therapy

ApothéCure is constantly striving to improve the dosing of some neurological drugs to aid in their delivery.  The most common changes in neurological drugs are alterations of dosage strength and form.

These changes are made frequently for physicians for the following reasons:

  • Products that have been removed from the market
  • Chemically sensitive patients who are in need of a specific medication
  • Needing a particular combination to increase patient compliance
  • Specialized release schedules of medications
  • Administration of a particular drug through alternative forms

Examples of some of the formulations we have made for physicians are:

  • 5-HTP
  • Acetyl L-Carnitine
  • Bromocriptine
  • Deprynyl
  • DHEA
  • DMAE
  • Ergoloid Mesylate
  • Gaba
  • GH-3
  • Gingko/Piracetam/Ergotamine MSM
  • Ginkgo/Selegeline
  • GPC: Glycerophosocholine
  • Ketamine
  • L-Carnitine
  • L-Tryptophan
  • Lidocaine
  • Lithium Orotate
  • Melatonin
  • Methysergide
  • Phosphatidlycholine
  • Phosphatidylserine
  • Piracetam
  • Pregnenolone
  • Promethazine
  • Rubidium chloride
  • Selegeline
  • Serotonin
  • Vinpocetine
Reference: Nootropics From Wikipedia, the free encyclopedia: http://en.wikipedia.org/wiki/Nootropic

 
Compounding Pharmacy - Safety Checklist Download the
Compounding
Pharmacy
Safety Checklist
Triple Protection for Your Patients and Practice

If you think you may have a medical emergency, please call your doctor or 911 immediately.
If you are seeking a referral or consultation with a medical or pharmacy expert, please contact us.
If you received spam that appears to have originated from us, please click here for important information.
Click here to read IMPORTANT DISCLAIMER information.

Last Modified: March 09 2010 20:40:47